TCGA-A2-A0ET-01A-31R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 36
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.300
- MYC_TARGETS_V1+0.270
- PROTEIN_SECRETION+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.260
- MYC_TARGETS_V2+0.230
- HEME_METABOLISM+0.210
- E2F_TARGETS+0.190
- DNA_REPAIR+0.170
- ANDROGEN_RESPONSE+0.130
- G2M_CHECKPOINT+0.090
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.650
- APICAL_SURFACE-0.450
- NOTCH_SIGNALING-0.450
- COAGULATION-0.430
- APICAL_JUNCTION-0.400
- ANGIOGENESIS-0.390
- HEDGEHOG_SIGNALING-0.380
- HYPOXIA-0.330
- MYOGENESIS-0.330
- TGF_BETA_SIGNALING-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A06N-01A-11R-A00Z-07 | — | B | 0.885 |
| 2 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.868 |
| 3 | TCGA-ZF-A9R4-01A-11R-A38B-07 | — | — | 0.856 |
| 4 | fe4a0710-a6db-4735-9d1a-113df310def6 | — | — | 0.844 |
| 5 | SRR2780299 | — | — | 0.840 |
| 6 | SRR1440763 | GTEX | — | 0.832 |
| 7 | SAMN03290898 | — | — | 0.831 |
| 8 | BS_DFGS950G | high-grade glioma | — | 0.827 |
| 9 | TCGA-A8-A09K-01A-11R-A00Z-07 | — | B | 0.826 |
| 10 | TCGA-C8-A1HO-01A-11R-A13Q-07 | — | B | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.230 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.130 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.050 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.020 | Remibrutinib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.010 | Inavolisib | — uncovered |